A new treatment of ischemic bowel disease: steroid delivery via retrograde venous route.
The present therapeutic approach to occlusive mesenteric disease is unable to alter its high mortality and morbidity. We attempted to stabilize the intestinal lysosomal population with steroid prior to revascularization and thus reduce the lysosomal effluent. Steroid delivery during the occlusive period was accomplished via retrograde venous flow in the portal system. During revascularization steroid was further infused via the superior mesenteric artery. Our experimental model compared systemic venous delivery with retrograde portal venous delivery of steroid. Analysis of tissue acid phosphatase levels suggested steroid delivery via retrograde portal venous flow is the most efficient method of lysosomal stabilization.
D000818:Animals; D004285:Dogs; D007263:Infusions, Parenteral; D007413:Intestinal Mucosa / Q000378:metabolism; D007421:Intestine, Small / Q000098:blood supply*; D007511:Ischemia / Q000188:drug therapy* / Q000378:metabolism; D007545:Isoproterenol / Q000008:administration & dosage* / Q000627:therapeutic use; D008638:Mesenteric Arteries; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D011169:Portal Vein
D007545:Isoproterenol; D008775:Methylprednisolone